Innoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT

Date : 04/21/2017 @ 8:00AM
Source : Business Wire
Stock : Innoviva, Inc. (MM) (INVA)
Quote : 13.07  0.1 (0.77%) @ 11:21AM
Innoviva, Inc. share price Chart

Innoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT

Innoviva, Inc. (NASDAQ:INVA)
Historical Stock Chart

3 Months : From Mar 2017 to Jun 2017

Click Here for more Innoviva, Inc. Charts.

Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the first quarter ended March 31, 2017 after market close on Thursday, April 27, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m. EDT/2:00 p.m. PDT to discuss the financial results and provide a corporate update.

To participate in the live call, dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers, and enter Conference ID: 4743061. A live webcast of the call will be available at: http://edge.media-server.com/m/p/7vf4ydi7 or from the investor relations section of the company website at www.inva.com and will be archived for 30 days. A telephone replay of the call will be available through May 3 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering Conference ID: 4743061.

About Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc., including the closed triple combination therapy for COPD. For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Innoviva, Inc.Eric d'Esparbes, 650-238-9640Senior Vice President and Chief Financial Officerinvestor.relations@inva.com

Latest INVA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20170626 15:37:42